High expression of INHBA is an adverse prognostic factor for de novo acute myeloid leukemia

References

• Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14:497–529.
   PubMed Web of Science ®Google Scholar
• Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115–136.
   PubMed Web of Science ®Google Scholar
• Giles FJ, Keating A, Goldstone AH, et al. Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2002;2002:73–110.
   Google Scholar
• Renneville A, Roumier C, Biggio V, et al. Cooperating gene mutations in acute myeloid leukemia: a review of the literature. Leukemia. 2008;22:915–931.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–447.
   PubMed Web of Science ®Google Scholar
• Gaddy-Kurten D, Tsuchida K, Vale W. Activins and the receptor serine kinase superfamily. Recent Prog Horm Res. 1995;50:109–129.
   PubMedGoogle Scholar
• Vale W, Rivier C, Hsueh A, et al. Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res. 1988;44:1–34.
   PubMedGoogle Scholar
• Boitani C, Stefanini M, Fragale A, et al. Activin stimulates Sertoli cell proliferation in a defined period of rat testis development. Endocrinology. 1995;136:5438–5444.
   PubMed Web of Science ®Google Scholar
• Yoshinaga K, Mimori K, Yamashita K, et al. Clinical significance of the expression of activin A in esophageal carcinoma. Int J Oncol. 2003;22:75–80.
   PubMed Web of Science ®Google Scholar
• Yoshinaga K, Yamashita K, Mimori K, et al. Activin a causes cancer cell aggressiveness in esophageal squamous cell carcinoma cells. Ann Surg Oncol. 2008;15:96–103.
   PubMed Web of Science ®Google Scholar
• Wildi S, Kleeff J, Maruyama H, et al. Overexpression of activin A in stage IV colorectal cancer. Gut 2001; 49:409–417.
   PubMed Web of Science ®Google Scholar
• Kleeff J, Ishiwata T, Friess H, et al. Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer. 1998;77:860–868.
   PubMed Web of Science ®Google Scholar
• Thomas TZ, Wang H, Niclasen P, et al. Expression and localization of activin subunits and follistatins in tissues from men with high grade prostate cancer. J Clin Endocrinol Metab. 1997;82:3851–3858.
   PubMed Web of Science ®Google Scholar
• Zheng W, Luo MP, Welt C, et al. Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer. Gynecol Oncol. 1998;69:23–31.
   PubMed Web of Science ®Google Scholar
• Seder CW, Hartojo W, Lin L, et al. Upregulated INHBA expression may promote cell proliferation and is associated with poor survival in lung adenocarcinoma. Neoplasia. 2009;11:388–396.
   PubMed Web of Science ®Google Scholar
• Seder CW, Hartojo W, Lin L, et al. INHBA overexpression promotes cell proliferation and may be epigenetically regulated in esophageal adenocarcinoma. J Thorac Oncol. 2009;4:455–462.
   PubMed Web of Science ®Google Scholar
• Wang Q, Wen YG, Li DP, et al. Upregulated INHBA expression is associated with poor survival in gastric cancer. Med Oncol. 2012;29:77–83.
   PubMed Web of Science ®Google Scholar
• Oshima T, Yoshihara K, Aoyama T, et al. Relation of INHBA gene expression to outcomes in gastric cancer after curative surgery. Anticancer Res. 2014;34:2303–2309.
   PubMed Web of Science ®Google Scholar
• Okano M, Yamamoto H, Ohkuma H, et al. Significance of INHBA expression in human colorectal cancer. Oncol Rep. 2013;30:2903–2908.
   PubMed Web of Science ®Google Scholar
• Lee HY, Li CC, Huang CN, et al. INHBA overexpression indicates poor prognosis in urothelial carcinoma of urinary bladder and upper tract. J Surg Oncol. 2015;111:414–422.
   PubMed Web of Science ®Google Scholar
• Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–951.
   PubMed Web of Science ®Google Scholar
• Fuss IJ, Kanof ME, Smith PD, et al. Isolation of whole mononuclear cells from peripheral blood and cord blood. Curr Protoc Immunol. 2009;85:7.1.1–7.1.8.
   Google Scholar
• Jin J, Wang JX, Chen FF, et al. Homoharringtonine-based induction regimens for patients with de-novo acute myeloid leukaemia: a multicentre, open-label, randomised, controlled phase 3 trial. Lancet Oncol. 2013;14:599–608.
   PubMed Web of Science ®Google Scholar
• Brothman AR, Persons DL, Shaffer LG. Nomenclature evolution: changes in the ISCN from the 2005 to the 2009 edition. Cytogenet Genome Res. 2009;127:1–4.
   PubMed Web of Science ®Google Scholar
• Dohner K, Schlenk RF, Habdank M, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood. 2005;106:3740–3746.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Breitruck J, et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group ULM. Blood. 2002;100:4372–4380.
   PubMed Web of Science ®Google Scholar
• Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115:453–474.
   PubMed Web of Science ®Google Scholar
• Tan S, Zhang L, Zhong XM, et al. Monoclonal antibodies against nucleophosmin mutants: potentials for the detection of acute myeloid leukemia. Int J Med Sci. 2011;8:309–314.
   PubMed Web of Science ®Google Scholar
• Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. JCO. 2004;22:3432–3433.
   PubMed Web of Science ®Google Scholar
• Uhlén M, Fagerberg L, Hallström BM, et al. Tissue-based map of the human proteome. Science. 2015;347:1260419.
   PubMed Web of Science ®Google Scholar
• Reis FM, Cobellis L, Tameirao LC, et al. Serum and tissue expression of activin a in postmenopausal women with breast cancer. J Clin Endocrinol Metab. 2002;87:2277–2282.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Seki N, Sugimoto T, et al. Identification of molecular targets in head and neck squamous cell carcinomas based on genome-wide gene expression profiling. Oncol Rep. 2007;18:1489–1497.
   PubMed Web of Science ®Google Scholar
• Hofland J, Timmerman MA, de Herder WW, et al. Expression of activin and inhibin subunits, receptors and binding proteins in human adrenocortical neoplasms. Clin Endocrinol (Oxf). 2006;65:792–799.
   PubMed Web of Science ®Google Scholar
• Panopoulou E, Murphy C, Rasmussen H, et al. Activin A suppresses neuroblastoma xenograft tumor growth via antimitotic and antiangiogenic mechanisms. Cancer Res. 2005;65:1877–1886.
   PubMed Web of Science ®Google Scholar
• Jakowlew SB. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006;25:435–457.
   PubMed Web of Science ®Google Scholar
• Frohling S, Schlenk RF, Kayser S, et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. Blood. 2006;108:3280–3288.
   PubMed Web of Science ®Google Scholar
• Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481–3485.
   PubMed Web of Science ®Google Scholar
• Schoch C, Kern W, Krawitz P, et al. Dependence of age-specific incidence of acute myeloid leukemia on karyotype. Blood. 2001;98:3500.
   PubMed Web of Science ®Google Scholar
• Verhaak RG, Goudswaard CS, van Putten W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood. 2005;106:3747–3754.
   PubMed Web of Science ®Google Scholar
• Suzuki T, Kiyoi H, Ozeki K, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. Blood. 2005;106:2854–2861.
   PubMed Web of Science ®Google Scholar
• Nakamura T, Takio K, Eto Y, et al. Activin-binding protein from rat ovary is follistatin. Science. 1990;247:836–838.
   PubMed Web of Science ®Google Scholar